Drug Origin Transparency Act of 2026
- Sponsor
- Rep. Matsui, Doris O. [D-CA-7]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 16, 2026
Bottom line
The bill aims to increase transparency in the pharmaceutical supply chain by requiring more frequent and detailed reporting to the FDA and clearer labeling of drug origins for consumers and downstream manufacturers.
What it actually does
This bill, the 'Drug Origin Transparency Act of 2026,' amends the Federal Food, Drug, and Cosmetic Act to significantly enhance reporting and labeling requirements for drug manufacturers. It mandates that drug companies provide detailed information to the FDA about their supply chains, including the identity and amounts from suppliers of active pharmaceutical ingredients (APIs) and other materials, with reports potentially required quarterly. Additionally, it requires drug labels and certificates of analysis to explicitly state the name, place of business, and unique facility identifier of the original manufacturer of the drug and its active pharmaceutical ingredients, along with other manufacturers, packers, or distributors.
Proponents argue
Proponents argue that this bill is crucial for enhancing drug supply chain security and resilience, especially in light of past drug shortages and quality concerns. By providing greater visibility into the origin of active pharmaceutical ingredients and manufacturing processes, it would enable the FDA to better monitor potential vulnerabilities, prevent counterfeiting, and respond more effectively to disruptions. Increased transparency would also empower healthcare providers and consumers with critical information about the drugs they use, fostering greater trust and accountability within the pharmaceutical industry.
Opponents contend
Opponents might contend that these new reporting and labeling requirements impose significant new regulatory burdens and costs on pharmaceutical manufacturers, particularly smaller companies, which could stifle innovation or lead to higher drug prices. They may also raise concerns about the potential for proprietary supply chain information to become public, thereby compromising trade secrets and competitive advantages. Furthermore, some might argue that the FDA already possesses sufficient authority to address supply chain issues and that these additional mandates are overly prescriptive or redundant.
The bill is short and relatively straightforward, allowing for a quick read and initial understanding within minutes. However, its implications for the complex pharmaceutical supply chain warrant deeper consideration.
Section 2(a)
Enhanced Supply Chain Reporting to FDA
This provision requires drug manufacturers to submit more detailed and frequent reports to the FDA about their supply chains. Specifically, these reports must identify the suppliers of active pharmaceutical ingredients (APIs), API intermediates, and in-process materials, as well as the amounts of drugs produced using materials from each supplier. The FDA Secretary can specify the exact information and reporting schedule (up to quarterly) through regulations or guidance.
Supporters argue
Supporters argue this provision is essential for identifying and mitigating vulnerabilities in the drug supply chain, which became evident during recent public health crises. Knowing the origin and flow of critical ingredients allows the FDA to proactively address potential shortages, quality control issues, and national security risks associated with reliance on single or foreign suppliers.
Critics contend
Critics might argue that mandating such granular and frequent reporting places an undue administrative and financial burden on manufacturers, potentially diverting resources from research and development or increasing operational costs that could be passed on to consumers. They may also express concerns about the protection of proprietary supply chain information.
Tradeoffs
The provision balances the public interest in a secure and transparent drug supply chain against the potential for increased regulatory burden and disclosure of sensitive business information for pharmaceutical companies.
Section 3
Mandatory Origin Labeling for Drugs and APIs
This section amends Section 502 of the FD&C Act to require that drug labels, including those for active pharmaceutical ingredients (APIs), clearly display the name, place of business, and unique facility identifier of the original manufacturer of the drug or API. It also extends this requirement to certificates of analysis for APIs. Furthermore, drug labeling must include the names and places of business for the original API manufacturer, any subsequent manufacturers, and the packer or distributor. The Secretary can allow for reasonable variations or alternative (e.g., electronic) placement of these labeling details.
This clause clarifies the effective date for the new detailed supply chain reporting requirements, linking it to the issuance of final regulations or guidance by the Secretary, but also ensuring that the general reporting requirement (as per existing law) remains unaffected by the absence of such new guidance.
Section 2(a)(2)(D)
Why it matters:This is standard legislative practice to provide a transition period for new regulations and to ensure existing law isn't inadvertently nullified while new rules are being developed.
Case for: This phased implementation allows the FDA and industry time to develop and adapt to the new reporting standards, preventing immediate disruption. It also ensures that the fundamental reporting obligations continue even if the specific new details take time to finalize.
Case against: Some might argue that delaying the full implementation of detailed reporting until regulations are finalized could prolong vulnerabilities in the supply chain. Others might contend that the broad discretion given to the Secretary in defining 'additional information' and 'reporting schedule' could lead to uncertainty for industry.
Estimated impact: Ensures a structured rollout of new reporting requirements, potentially delaying the full benefit of enhanced transparency by at least 6 months post-guidance.